Cadrenal Therapeutics Inc
NASDAQ:CVKD
Intrinsic Value
The intrinsic value of one CVKD stock under the Base Case scenario is 5.16 USD. Compared to the current market price of 15.68 USD, Cadrenal Therapeutics Inc is Overvalued by 67%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
Cadrenal Therapeutics Inc
Fundamental Analysis

Revenue & Expenses Breakdown
Cadrenal Therapeutics Inc
Balance Sheet Decomposition
Cadrenal Therapeutics Inc
Current Assets | 10.1m |
Cash & Short-Term Investments | 10m |
Receivables | 38.2k |
Other Current Assets | 56.7k |
Non-Current Assets | 10.7k |
PP&E | 6.9k |
Other Non-Current Assets | 3.8k |
Free Cash Flow Analysis
Cadrenal Therapeutics Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Cadrenal Therapeutics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-11m
USD
|
Operating Income
|
-11m
USD
|
Other Expenses
|
309.2k
USD
|
Net Income
|
-10.7m
USD
|
CVKD Profitability Score
Profitability Due Diligence
Cadrenal Therapeutics Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
Score
Cadrenal Therapeutics Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
CVKD Solvency Score
Solvency Due Diligence
Cadrenal Therapeutics Inc's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Score
Cadrenal Therapeutics Inc's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CVKD Price Targets Summary
Cadrenal Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for CVKD is 36.38 USD with a low forecast of 30.3 USD and a high forecast of 47.25 USD.
Dividends
Current shareholder yield for CVKD is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one CVKD stock under the Base Case scenario is 5.16 USD.
Compared to the current market price of 15.68 USD, Cadrenal Therapeutics Inc is Overvalued by 67%.